Stocks making the biggest moves midday: Regeneron, Dominion, Mobileye, Viking and more

Midday trading was driven by company-specific catalysts: Dominion Energy jumped more than 9% on a reported all-stock acquisition by NextEra Energy, while NextEra fell about 5% on the deal. Other notable movers included Cognizant (+7%) and Boston Scientific (+3%) on aggressive buyback plans, ServiceNow (+6%) on a Bank of America buy rating, and Bio-Rad (+11%) on Elliott activity. On the downside, Regeneron dropped more than 10% after a late-stage trial miss, while Mobileye fell almost 8% on a Jefferies underperform initiation.

Analysis

The clearest signal here is not the headline movers but the renewed appetite for balance-sheet actions as a stock-specific catalyst. Companies announcing buybacks or capital allocation shifts are being rewarded because the market is treating repurchases as a higher-conviction earnings lever than organic growth in a slower-demand tape; that favors names with visible free cash flow and penalizes those where the story is still execution-heavy. The second-order effect is that capital-return beneficiaries can keep rerating even if the macro backdrop stays choppy, because the bid is coming from incremental EPS support rather than multiple expansion alone.

The more important dispersion trade is in healthcare and industrial tech. The negative reaction in the oncology read-through is likely to bleed into other late-stage, single-asset biotech names with near-term binary trial risk, while larger diversified med-tech platforms should see a relative premium as investors rotate toward companies that can offset product setbacks with repurchases and tuck-in capital deployment. In software, the AI narrative is increasingly bifurcating: platforms with workflow lock-in are being re-rated as AI beneficiaries, while point solutions and hardware-adjacent autonomy plays look more vulnerable to margin compression and slower monetization.

The Berkshire signaling should not be overinterpreted as a macro call; the more actionable read is that a known long-duration allocator is leaning into cash-generative, under-owned sectors where sentiment is still skeptical. That creates a short-term momentum tailwind for the targeted names, but the durability depends on whether additional filers and follow-on ownership disclosures appear over the next 1-2 quarters. If not, the move in some of these names could fade once the novelty premium is arbitraged away.

Key Decisions for Investors

• Long BSX vs short REGN for 1-3 months: own the diversified med-tech capital-return winner and fade the binary biotech drawdown; target 8-12% relative outperformance if trial-driven de-risking continues.
• Add NOW on pullbacks over the next 2-4 weeks: the market is paying up for AI-enabled workflow incumbents, and the risk/reward still skews positive as long as enterprise spend remains intact; use a 5-7% trailing stop.
• Short MBLY or buy put spreads for 1-2 months: competitive pressure plus lofty autonomy expectations create asymmetric downside if EV/ADAS adoption slows; target a move toward the low end of recent trading ranges.
• Pair long CTSH / short lower-quality IT services over 1-2 quarters: capital returns plus AI services exposure should support multiple expansion versus vendors that still depend on legacy maintenance revenue.
• Trade VIK long only on weakness into the next booking update: demand resilience can persist for several quarters, but after the pop, upside is more limited unless booking acceleration re-accelerates; use a tight risk budget because travel names can reprice quickly on geopolitical headlines.